Evidence map›Paper›PMID 41893024›Full record

ReviewJournal of personalized medicine2026

Beyond Glycemia: Pharmacology-Driven Ketogenesis and Euglycemic DKA with SGLT2 Inhibitors-A Practical Review for Acute Care.

Massimo Meco, Emiliano Agosteo, Pierluigi Zulli, Fulvio Nisi, Enrico Giustiniano

Abstract readReview
In one paragraph

Review in Journal of personalized medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Massimo MecoDepartment of Anaesthesia and Intensive Care, San Carlo Clinic, 20037 Paderno Dugnano, Italy.ORCID 0000-0003-4844-2476
Emiliano AgosteoDepartment of Anaesthesia and Intensive Care, San Carlo Clinic, 20037 Paderno Dugnano, Italy.
Pierluigi ZulliDepartment of Anaesthesia and intensive Care, European Hospital, 00149 Rome, Italy.
Fulvio NisiDepartment of Anesthesia and Intensive Care, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.ORCID 0000-0003-1975-5473
Enrico GiustinianoDepartment of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are widely prescribed for type 2 diabetes, heart failure, and chronic kidney disease. A rare but dangerous adverse event is SGLT2i-associated diabetic ketoacidosis, often euglycaemic (euDKA), and therefore easy to miss. This narrative review summarizes mechanisms, triggers (fasting, dehydration, infection, perioperative stress), and ketone-centred pathways for diagnosis, treatment, and prevention in acute-care settings. Management priorities are volume resuscitation, blood β-hydroxybutyrate and acid-base testing, insulin infusion with dextrose to suppress ketogenesis, and electrolyte replacement. Prevention relies on "sick-day" rules, perioperative drug withholding, and a low threshold for ketone testing in any patient with high-anion-gap acidosis, despite normal or mildly elevated glucose.

Indexed as

beta-hydroxybutyrateemergency departmenteuglycemic diabetic ketoacidosishigh anion gap metabolic acidosisperioperative managementSGLT2 inhibitorssick-day rules

Identifiers

PMID41893024
PMCPMC13027608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.